Comparison of thrombotic adverse events in patients treated with factor VIII products and emicizumab using the 2018-2022 US Food and Drug Administration Adverse Event Reporting System data: comment from Berkowitz et al.

Autor: Berkowitz C; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA., Wilson S; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA., Key NS; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA., Ellsworth P; Department of Medicine, Division of Hematology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA; University of North Carolina Blood Research Center, Chapel Hill, North Carolina, USA. Electronic address: patrick_ellsworth@med.unc.edu.
Jazyk: angličtina
Zdroj: Journal of thrombosis and haemostasis : JTH [J Thromb Haemost] 2024 Sep; Vol. 22 (9), pp. 2674-2675.
DOI: 10.1016/j.jtha.2024.04.027
Abstrakt: Competing Interests: Declaration of competing interests C.B. has no relevant disclosures. S.W. has no relevant disclosures. N.S.K. has been a consultant for Biomarin, Uniqure/CSL, and Centessa and chairs an Investigator Initiated Studies (IIS) grants review panel for Novo Nordisk. P.E. has research funding from Novo Nordisk (Novo Nordisk Access to Insight Basic Research Grant) and has been a consultant for Genentech.
Databáze: MEDLINE